Eli Lilly Inks $1.26 Billion Deal for South Korean Digestive Disease Treatment

Seoul, Monday, 1 June 2026.
In late May 2026, Eli Lilly committed up to $1.26 billion for Hanmi Pharmaceutical’s digestive drug candidate, sparking a nearly 17 percent surge in the South Korean biotech’s shares.